AZD1390 for Glioblastoma
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but it does mention that you cannot use certain medications like coumarin-derived anticoagulants and strong inhibitors or inducers of CYP3A4. It's best to discuss your current medications with the trial team to see if any adjustments are needed.
What data supports the effectiveness of the drug AZD1390 for glioblastoma?
What makes the drug AZD1390 unique for treating glioblastoma?
AZD1390 is unique because it inhibits the ataxia-telangiectasia mutated kinase, a key regulator of the DNA damage response, which can enhance the effectiveness of radiation therapy in treating glioblastoma. Despite challenges in crossing the blood-brain barrier, it achieves effective concentrations in tumor areas, making it a promising option for radiosensitization in brain tumors.12367
What is the purpose of this trial?
This trial tests a new drug, AZD1390, combined with radiation therapy in patients with severe brain cancer. AZD1390 is designed to enhance the effectiveness of radiation in killing cancer cells.
Research Team
Nader Sanai, MD
Principal Investigator
Chief Scientific Officer/Director
Eligibility Criteria
This trial is for adults over 18 with newly diagnosed or recurrent WHO Grade 4 glioma (a type of brain tumor) who are planning to have radiation. They must have measurable disease, stable seizures if present, and good organ function. Pregnant women, those with certain heart conditions or severe infections, and individuals on specific medications are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 0
Participants undergo pharmacokinetic analysis of AZD1390 in tumor tissue
Phase 1b Expansion
Participants receive therapeutic dosing of AZD1390 plus standard-of-care fractionated radiotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AZD1390
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nader Sanai
Lead Sponsor
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Ivy Brain Tumor Center
Collaborator
Barrow Neurological Institute
Collaborator